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Abstract
Despite great advances have been made in oncologic approaches, the morbidity and 
 mortality caused by colon cancer are still overwhelming. Particularly, the intra- and 
inter-tumour heterogeneity makes accurate sampling challenging and often leads to fail-
ure of even modern therapeutic strategies. Moreover, tumour molecular genotype can 
suffer alterations over time, triggering suboptimal therapeutic outcomes as a result of 
irrelevant information provided by histological biopsies. Daily, tumour cells shed into 
the bloodstream at the early stages of the disease. These circulating tumour cells (CTCs) 
can be detected and analysed after enrichment, providing this way valuable informa-
tion in real time. Furthermore, apoptotic and/or necrotic tumour cells discharge DNA 
fragments into the circulating bloodstream. Elevated levels of these so-called circulating 
tumour DNA (ctDNA) fragments can be identified in the peripheral blood of patients as 
compared to healthy individuals. In this view, the detection and characterization of the 
CTCs and ctDNA are a real-time “liquid biopsy” that has been developed for accurate 
tumour monitoring and molecular characterization. This modern non-invasive analyti-
cal approach allows consecutive sampling to monitor CTC number and tumour genetic 
changes over time without the need of tissue biopsy. Consequently, “liquid biopsies” can 
be used to screen for cancer, stratify patients to the optimum treatment and to monitor 
the patient’s response to treatment or identify treatment resistance. This chapter offers 
an overview of the following approaches with respect to liquid biopsies: CTCs and 
ctDNA. Some of the analytical techniques and challenges in the detection of these rare 
events will also be presented here.
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1. Introduction
Uncontrolled division and growth of human cells and subsequent invasion to other tissue via 
the circulatory and the lymphatic systems are commonly known as cancer.
One of the cancer types known to affect the gastrointestinal (GI) tract and rated third most 
commonly diagnosed form irrespective of gender is colorectal cancer (CRC).
In a context outlined by alarming figures of both prevalence (with a lifetime CRC risk of 5.1%) 
and high mortality rate, CRC being second in line among cancer-related causes of deaths in 
both genders, advances in therapy have become particularly significant; thus, in addition to 
established liver resection, outcomes in survival rate have been greatly improved in recent 
years due to better means for earlier detection, advances in chemotherapy and therapies 
based on biological agents.
Largely studied nowadays, factors influencing the likelihood of developing CRC are a close 
family history of genetic changes in that respect (20% of cases), notably associated with cer-
tain genetic syndromes such as the Lynch syndrome (hereditary nonpolyposis colorectal can-
cer, HNPCC) in ca. 3% of cases [1] and familial adenomatous polyposis with its variant the 
Gardner syndrome (in a further ca. 1% of CRC instances).
HNPCC-related CRC risk factors include early onset (ca. 44 average age) triggered by an auto-
somal dominant inheritance, development in 70% of cases in splenic flexure proximity as well 
as a surplus of synchronous (18% of all patients) and metachronous CRC (45% of patients) 
following segmental resection or hemicolectomy. In addition to a CRC cause, Lynch syn-
drome frequently also results in other carcinoma types such as ovary and endometrial, other 
gastrointestinal location (stomach, small intestine), pancreas as well as transitional carcinoma 
in the renal pelvis and the ureter [2].
This high metastatic disease potential is the main cause of CRC lethal outcome and may be 
attributed to the contribution of a specific gene (I(MACCI)); already isolated [3], this is a tran-
scriptional factor able to influence the expression of the hepatocyte growth factor and there-
fore associated with proliferation of CRC cells, scattering and new tissue invasion and further 
tumour growth and metastasis, as shown in cell cultures and animal studies in mice. MACCI 
close involvement as contributor to occurrence of metastasis makes it a novel target for CRC 
approach, which needs confirmation by further studies and clinical trials [4].
Contribution of genetic factors in CRC development combines with action of epigenetic ones 
at cell level.
However important the role of genetic features, most CRC may rather be the outcome of 
chronic intestinal inflammation preceding tumour development, gut microbiota and such 
environmental factors as life style (diet included) and food and environmental-borne muta-
gens [5, 6].
Among chronic intestinal inflammations responsible for CRC risk, inflammatory bowel  disease 
(under 2% of CRC cases every year [7]), Crohn’s disease and ulcerative colitis need special 
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mention for being the frequent cause of tumour growth [8], the risk growing with the sever-
ity of inflammation and the duration of the disorder [9]. Statistically, in that respect, 10 years’ 
duration of Crohn’s disease results in CRC in 2% of patients, and the risk increases four times 
and nine times for 20 and 30 years’ durations, respectively [7]. On the other hand, a history of 
over 30 years of ulcerative colitis results in development of some type of cancer precursor or 
CRC in ca. 16% patients [7].
2. Tumour progression
As regards CRC development, it typically originates in benign, premalignant or malignant 
polyps occurring at the level of the colon or rectum epithelial lining (as, for instance, hyper-
plastic polyps, tubular adenoma or colorectal adenocarcinoma, respectively). Such abnormal-
ities are the result of inherited or acquired oncogenic and inactivating mutations revealed by 
complex genome scale analysis, which has shown the existence of hypermutated and non-
hypermutated CRC tumour categories [10].
Among non-hypermutated types, one commonly occurring mutation affects the Wnt signal-
ling pathway, leading to increased signalling activity and emerging at the level of the intesti-
nal crypt stem cell [11].
Most frequently, the mutated CRC-related gene is the APC gene. APC protein prevents 
β-catenin protein accumulation. The absence of APC leads to β-catenin accumulation and 
translocation to the cell nucleus, where it binds to the DNA, thus activating transcription of 
proto-oncogenes. Although normally playing an important role in stem cell renewal and dif-
ferentiation, when inappropriately expressed and highly accumulated, these proto-oncogene 
products can induce cancer.
In addition to the absence of the APC protein, high β-catenin-related CRC may also be deter-
mined by β-catenin (CTNNB1) mutation, blocking its very own breakdown, or occurrence of 
mutations in other APC similarly operating genes (e.g., AXINI, AXIN2, NKDI, TCF71.2) [12].
Besides deficient Wnt signalling pathways, realization of the cancer potential requires addi-
tional mutations. Usually, action of Wnt pathway defects is prevented by intervention of the 
cell division monitoring p53 protein, a product of the TP53 gene, which normally eliminates 
flawed cells. Thus, a mutation arising in the TP53 gene may reverse the potential from benign 
epithelial tumour cell into invasive epithelial cell.
If not affecting the p53-encoding gene, mutations may instead target a different protein play-
ing a protective role, i.e., the BAX12 but also ARDI A, CTNNB I, SOX9, FAM123B and ATM.
On the other hand, hypermutated tumours progress through specific genetic events and dis-
play MSH3, MSH6, TGFBR2, ACVR2A, SLC9A9, BRAF and TCF71.2 mutated forms.
Whichever the tumour type, all these genes are involved in the Wnt and TGF-β signalling path-
ways, leading to higher MYC activity, as major CRC factor [13]. Role of “field defects”/“field 
cancerisation”, the concept first emerged in the early 1950s to refer to an area of the epithelium 
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featuring a preconditioning responsible for cancer predisposition of the area in question [14]. 
Despite unclear origins at the time of their introduction, the terms define premalignant tissue 
as potential sites for new cancer.
In time, research has progressively emphasized the importance of “field defects” in advance 
to CRC, and the assumption was confirmed by studies showing almost the exclusive use of 
discrete neoplastic foci for in vitro research and well-defined tumours for in vivo studies [15] 
in all cancer research.
In addition, as research further indicated, the majority of somatic mutations occurring at 
tumour level emerged during development of apparently normal cells [16], at the site of “field 
defects” (and therefore in preneoplastic stage).
A further addition to terminology refers to the term “aetiologic field effect”, based on the 
“field defect” concept and referring to molecular and pathologic changes in preneoplastic 
cells at molecular level. The term also covers the extent to and manner in which exogenous 
environmental factors as well as molecular changes in the local microenvironment influence 
neoplastic progression throughout [17].
3. Epigenetic factors in tumour growth
However important mutation-induced genetic alterations, epigenetic alterations are significantly 
more common in CRC and involve hundreds of genes. As revealed by research, (Vogelstein and 
colleagues) oncogene mutations and suppressor mutations (both known as “driver mutations”) 
are rather limited in average CRC forms (1–2 and 1–5, respectively), although accompanied by 
an estimated 60 additional so-called “passenger” mutations [18].
Common types of epigenetic cancer-related alterations modifying gene expression levels 
by action on the different types of RNA (miRNAs) may involve abnormal methylation 
of DNA in tumour suppressor promoters [19], such as reduced expression of miR-137 
because of methylation of the miR-137-encoding DNA sequence in the CpG island [20]. 
Altered miR-137 expression triggers drastic (2- to 20-fold) alteration of mRNA expression 
of the target genes and related slighter changes in expression of proteins produced by the 
genes.
There are further microRNAs, of comparable numbers of target genes, which undergo even 
more frequent epigenetic alterations of field defects in the colon, resulting in specific CRC 
forms [21].
As common is direct hyper-/hypo-methylation of CpG islands of protein-encoding genes as 
well as histone alterations or modification of chromosomal architecture, with influence on 
gene expression [22]. Research has recently outlined the potential of early epigenetic decline 
in expression of DNA repair enzyme as cause of cancer characteristic genomic and epig-
enomic instability [18].
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4. Colorectal cancer (CRC)
4.1. CRC clinical manifestations
Although CRC clinical signs vary with tumour location in the intestine as well as with the pres-
ence of metastases, medical practice has outlined certain warning signs and symptoms now 
considered typical, such as loss of appetite, weight loss, vomiting and/or nausea, rectal bleed-
ing and anaemia in the over 50 age group [23], severe and persistent constipation and modified 
stools (accompanied by blood elimination and/or diminished thickness) [24]; weight loss and 
changed bowel habit may be considered a warning only if accompanied by bleeding [22].
4.2. CRC diagnosis
4.2.1. Diagnostic steps
Typically, CRC may be diagnosed by the sampling of colon areas suspected of tumour devel-
opment during procedures suitable for the lesion site, i.e. colonoscopy or sigmoidoscopy.
Once the tumour is confirmed, the level of the disease needs to be determined, which is gener-
ally done by a CT scan involving the chest, abdomen and pelvis, but also by position imaging 
tomography and MRI, for certain cases.
The next diagnostic step is to determine the stage of the tumour, based on the TNM cancer 
staging system (where T stands for primary tumour stage, N for the presence of regional 
lymph nodes and M for remote metastasis). Staging criteria include the extent of initial 
tumour spreading, the presence and site of lymph nodes and the metastasis level [25].
4.2.2. Microscopic examination
Adenocarcinoma is a malignant tumour of the epithelium, whose source lies in the superfi-
cial glandular epithelial cells of the colon and cecum lining. This tumour invades the colon/
cecum wall and further progressively permeates the respective layers (first the muscularis 
mucosae, then the submucosa and lastly the muscularis propria). Tumour cells in question 
are organized as irregular tubular, multistratified structures, featuring multiple lumens and 
decreased stroma (in a back-to-back growth pattern). In addition, in some cases, tumour cell 
lacks of cohesion may be observed, as well as a secretion of mucus pervading the interstitium 
and resulting in extensive mucus/colloid (optically “empty” spaces) pools (forming the so 
called “mucinous (colloid)”), poorly differentiated adenocarcinoma. Mucus remaining within 
the walls of the tumour cell drives the nucleus towards the cell membrane, and the “signet-
ring cell” emerges.
In fact, differentiation may vary in adenocarcinoma, contingent on cellular pleomorphism, 
glandular architecture and muco-secretion of the predominant pattern; thus, three variants of 
adenocarcinoma may be observed as regards the degree of cell differentiation: well differenti-
ated, moderately differentiated and poorly differentiated [26].
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CRC cell characteristics may be determined by analysis of tissue samples harvested by biopsy 
or during surgery. The pathology report provides data on cell type and grade. In CRC, the 
most common cell (98% of cases) is adenocarcinoma, but other types may also occur in rare 
cases (squamous cell carcinoma and lymphoma) [27].
4.2.3. Immunochemistry
It is generally considered that more than half of CR adenomas and up to 90% of CRC tumours 
present overexpression of the COX (cyclooxygenase)-2, normally absent from healthy colon 
tissue but acting as fuel for abnormal cell growth [28].
The cancer variant may be determined by histologic examination.
4.2.4. Macroscopic examination
In order to predict the likely course of tumour progression and adequate management, mac-
roscopic examination looks closely at the site of the tumour in the intestine; thus, tumour 
development on the ascending colon and cecum (the right side of the large intestine) is most 
often exophytic (growing outwards from the bowel wall), which may in infrequent cases 
result in faecal obstruction, accompanied by anaemia.
Tumours growing on the left bowel side are largely peripheral and may result in obstruction 
of the bowel lumen and thinner stools [27].
4.3. CRC prevention
One key approach to CRC (as for other cancers, in fact) and unanimously recognized as such 
is prevention; closer surveillance and healthier lifestyle can essentially contribute to CRC 
prevention.
Therefore, research has greatly been focused on effective means in that respect, in all areas of 
intervention.
As regards lifestyle, diets are currently recommended to include more significant amounts of 
vegetables, fruits and whole grains and decrease consumption of white flour products, sugars 
and red meat.
As in other areas of healthcare, physical exercise has been proved to be beneficial, though 
less significant for preventing or reducing colon cancer risk [29, 30]. However, avoiding pro-
longed sitting as a daily routine is important [31].
Medication has also been the target of research, which has shown the potential of aspirin and 
celecoxib to reduce CRC danger in high-risk groups as determined by assessment of family 
medical history and other personal risk factors, though not in average risk ones [32–35].
Calcium supplementation is currently under study as well, not with sufficient evidence yet.
As for protection factors, in vitro studies have shown that intake and blood levels of vitamin 
D act as one, as have lactic acid bacteria, due to their antioxidant activity, immunomodulation 
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as well as promotion of programmed cell death, proliferative effects and epigenetic alteration 
of cancer cells [36].
Screening is an important and effective means for prevention and early detection of cancer in 
general and CRC in particular, the more so as most CRC cases (>80%) originate in adenoma-
tous polyps [37].
As mentioned above, screening is also a very important means for cancer diagnosis before the 
emergency of actual symptoms (by 2–3 years) [25].
Close relatives of HNPCC patients need accurate and structured screening, according to a 
well-designed programme and schedule [38], as in certain countries such as Canada, the 
United Kingdom, Australia and the Netherlands [39–41].
Therefore, these should undergo a first routine colonoscopy at the age of 25, which, as a rou-
tine, should be repeated every 3 years, in the case of negative results, and every year should 
an adenoma be found. In cases where routine colonoscopy reveals the presence of cancer, 
subtotal colectomy needs to be performed.
In addition, for women, ovarian ultrasound and endometrial biopsy need to be performed as 
early as 25 years old.
Screening tests have been devised and researched, current practice now relying mostly on 
colonoscopy (both standard and virtual via CT scan), faecal occult blood testing, multitarget 
stool DNA screening and flexible sigmoidoscopy [25].
Although with proven efficacy in other respects, sigmoidoscopy is the only procedure able to 
provide screening of the right side of the colon, the site for almost half (42%) of malignancies  [42].
Equally effective, standard colonoscopy is less costly than virtual colonoscopy via CT scan 
and avoids the additional risk of exposure to radiation and also able to eliminate any potential 
abnormal growth found [25].
In the 50–75 age group with standard risk factors, screening should include faecal occult 
blood testing or immunochemical testing every 2 years; an alternative is performance of sig-
moidoscopy every 10 years, to the detriment of colonoscopy [43].
For patients with familial adenomatous polyposis, the high-malignancy risk may be offset by 
total proctocolectomy, ensuring elimination of the risk of both colon and rectal cancers [44].
4.4. CRC management
Given CRC’s incurable character, therapeutic decisions in that respect can only be directed to 
either cure or as a palliative, largely depending on tumour stage [45] but also on other factors 
as well, such as the patient’s health status and even preferences.
4.4.1. Therapy
Surgery can be a means leading to cure but in early stages only, whereas at later stages, when 
the metastatic disease has also been initiated, the curative potential of surgery decreases, and 
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palliation (alleviation of tumour-related symptoms and patient’s comfort and quality of life) 
becomes prevalent [25].
For the very first stage, one colonoscopy intervention can suffice to eliminate cancer [46], 
while the curative potential of surgery decreases with the tumour stage.
Therefore, one stage further, in localized cancers, cure may still be attempted through ample 
removal associated with ensuring adequate margins, which can be achieved laparoscopically 
or more often by open laparotomy [25], with colon reconnection, or by colostomy [46].
In the stage of a few emerging metastases, those in the lungs or liver may be eliminated.
In certain cases at this stage, surgery may be preceded by chemotherapy, in an attempt to 
minimize the tumour before removal.
If recurrence occurs, this mainly involves the lungs and liver [25].
4.4.2. Chemotherapy
This is administered in cases beyond stage 1 CRC, given the curing potential of surgery. No 
chemotherapy is also customary in CRC stage II; on condition no such risk factors as threats 
from negative lymph node sampling or the presence of a T4 tumour are present.
Chemotherapy is also not feasible in patients with identified abnormal mismatched repair 
genes.
On the contrary, chemotherapy is a must and an integral therapy component in stage II and 
stage IV CRC25, characterized by cancer spreading to remote organs or the lymph nodes; the 
use of the chemotherapeutic agents oxaliplatin, fluorouracil or capecitabine is instrumental in 
increasing life expectancy, with the disadvantage of debatable chemotherapy benefits in the 
case of cancer-free lymph nodes.
Turn to palliative care becomes necessary where CRC has become extensively metastatic or 
may not be resected, opening the alternative for several different chemotherapy medications 
[25], including, oxaliplatin, fluorouracil, capecitabine, irinotecan and tegafur/uracil [47, 48].
4.4.3. Radiotherapy
Given bowel sensitivity to radiation, patient with colon cancer treatment cannot benefit from 
addition of radiation to chemotherapy, although this may be effective for rectal cancer [25]. 
The same was for chemotherapy; radiotherapy may be used as neoadjuvant and adjuvant in 
certain rectal cancer stages only [49].
4.4.4. Palliation
For patients with incurable CRC forms, palliative care, though not a promising cure, may 
bring the benefit of better quality of the patient’s life both directly and indirectly, via the life 
of their families, lessening symptoms and anxiety and also reducing the need of hospital 
admission [50].
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Palliation is typically symptom directed and consists of procedures designed to improve 
symptoms or minimize the possibility of complications such as abdominal pain, tumour 
bleeding and/or bowel obstruction [51], thus contributing to improved quality of life.
Such procedures may include surgery, for elimination of cancer tissue to some extent, without 
attempting to cure, placement of a stent or performing a bypass of part of the bowel.
Non-surgical palliative care approaches include pain medication and/or radiotherapy aiming 
to reduce the tumour size [52].
4.4.5. Follow-up
The main purpose of follow-up is to obtain the earliest identification of later metachronous 
lesions, i.e., metastases or tumours not originating from the initial cancer [53].
As an underlying measure for cancer survivors, exercise as a mainstay of lifestyle may 
be useful as secondary therapy, as shown by results indicating important reduction in 
8- oxo-dG in the urine of patients after taking moderate exercise for 2 weeks of following 
primary therapy [54].
4.5. CRC prognosis
The most commonly used prognosis criterion is the 5-year survival rate, which is under 60% 
for CRC in Europe, whereas this is the cause of death for one third of CRC patients [25] in 
most developed countries. The reason for these unexpectedly low outcomes despite evident 
progress in new therapeutic means and their improved availability worldwide is mainly CRC 
late identification (stage IV already present in 20% of patients seeking medical attention), with 
potentially resectable isolated liver metastasis in ca. 25% of these patients. Of these 25%, one 
third of patients undergoing resection achieve 5-year survival [55, 56].
5. Liquid biopsy
Despite the major advances in cancer therapies, the morbidity and mortality associated with 
this disease are still enormous. Tumour heterogeneity holds the main responsibility underly-
ing inefficient treatment and failure of current therapeutic strategies, including the targeted 
therapies. For efficiency reasons, the molecular targeted therapies require constant monitor-
ing of the tumour genome, but harvesting consecutive tissue biopsies is very difficult and 
inconvenient for medical and economic reasons. Therefore, the lack of real-time information 
regarding tumour heterogeneity during the disease evolution most commonly results in the 
treatment failure and requires the development of novel approaches. In this view, liquid biop-
sies offer a tool for real-time screening of disease particularities, stratify patients for the best 
treatment and also monitor the response of the treatment. Due to their non-invasive nature, 
liquid biopsies can be used for repeated sampling to monitor tumour genetic alterations 
over time, avoiding this way consecutive tissue biopsies. Liquid biopsies analyse circulating 
tumour cells, cell-free tumour DNA and/or exosomes, known as tumour-circulating markers.
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5.1. Circulating tumour cells (CTCs)
Circulating tumour cells (CTCs) have been identified during the 1800s and presumed 
responsible for the metastatic process [57]. These cells are of epithelial origin and shed from 
the tumours in the peripheral blood of patients where they can be enriched, detected and 
analysed.
The detection of CTCs in the peripheral blood of patients with cancer holds a great promise 
for the future development of efficient anticancer therapies. However, due to the very low 
concentrations of CTCs in the peripheral blood (one tumour cell for millions of normal blood 
cells), their detection and identification still remain challenging and require high analytical 
sensitivity and specificity methods, which usually consist in a combination of enrichment and 
detection [58].
CTC enrichment strategies include a wide range of technologies based on those CTC particu-
larities that can discriminate them out of the normal haematopoietic cells. Concrete CTCs can 
be detected based on physical properties such as size, density, electric charges, deformability 
or biological properties such as cell surface marker expression and viability. CTC separation 
based on their physical properties holds the great advantage of being done without labelling 
the cells. Some of these methods include density gradient centrifugation, filtration, photo-
acoustic flow cytometry, microfluidics, etc. [59, 60].
Nevertheless, the biological properties of the CTCs hold a major role in their identification, 
mainly based on immunobead assays. These assays use antibodies targeting tumour-asso-
ciated antigens (positive selection) or leukocyte-specific antigens such as CD45 (negative 
selection) in order to detect and separate CTCs from the blood cells. The positive selection 
usually targets the epithelial cell adhesion molecule (EpCAM). Subsequently, CTCs are 
confirmed with antibodies against cytokeratins (CKs) [59]. Among the current EpCAM-
based technologies, the US Food and Drug Administration approved CellSearch® sys-
tem (Veridex) which is the current “gold standard” for all new CTC-detection methods. 
According to this standard, CTCs are nucleated cells that express the epithelial cell adhesion 
molecule and cytokeratins but lack the expression of the common leukocyte CD45 marker 
(EpCam+_CK18/19+_DAPI+_CD45− cells).
Interestingly, some CTCs undergo the epithelial to mesenchymal transition (EMT) and loose 
critical epithelial markers. Capturing CTCs’ lacking EpCAM expression requires the use of 
antibody cocktails against a panel of epithelial cell surface antigens such as HER2, MUC-1, 
EGFR and folate-binding protein receptor and against mesenchymal or stem cell antigens 
such as c-MET, N-cadherin and CD318 [61].
Regardless of the enrichment method, the isolated CTCs still contain a significant number of 
normal blood cells, and therefore CTCs should be next identified by a method that can dis-
criminate between malignant cells and normal blood cells. The CellSearch® system as well as 
other assays is based on the fluorescent staining of the cells for the following markers: CKs 
(positive marker), the common leukocyte antigen CD45 (negative marker) and a nuclear dye 
(4,6-diamidino-2-phenylindole, DAPI).
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Functional EPISPOT (for EPithelial ImmunoSPOT) assay has been introduced for CTC analy-
sis in order to detect only the viable CTCs, able to produce metastases [62].
Other alternatives to immunologic assays of viable CTC-detection target specific mRNAs. 
A commercially available RNA-based CTC assay is the AdnaTest™ (AdnaGen), which uses 
nonquantitative RT-PCR to identify cells that express the transcripts of tumour-specific genes 
after immunomagnetic capture of MUC-1, HER2 and EpCAM cells [63].
5.2. Circulating tumour DNA (ctDNA)
Cell-free DNA (cfDNA) is a powerful tool for its potential use in a wide range of clinical fields 
such as cancer research [64, 65], non-invasive prenatal testing [66] and transplant rejection 
diagnostics [67]. Most cfDNA in plasma is highly fragmented (150–180 bp) [68] with a higher 
prevalence of tumour-associated mutations in the shorter fragments [69]. In patients suffering 
from cancer, a fraction of the cfDNA is tumour-derived and is known as circulating tumour 
DNA (ctDNA).
cfDNA reaches the systemic circulation by various pathologic or normal physiologic mecha-
nisms [70]. However, with respect to solid tumours, the ctDNA is usually released as a result 
of necrosis or autophagy [71]. Notably, unlike apoptosis, necrosis generates larger DNA frag-
ments [72]. Cancer patients generally have much higher levels of cfDNA than healthy indi-
viduals [73, 74]. ctDNA carries genomic and epigenomic alterations according to the tumour 
genomic alterations (copy number variation, point mutations, microsatellite instability, 
degree of integrity, loss of heterozygosity, rearranged genomic sequences, DNA methylation, 
etc.) [75]. Only on the basis of these biological characteristics, ctDNA can be discriminated 
from normal cfDNA. Consequently, after its validation ctDNA could be used as a specific bio-
marker that provides personalized information to detect residual disease or monitor tumour 
progression during therapy.
Due to the high degree of fragmentation as well as the small fraction of ctDNA within the 
cfDNA, the analysis of ctDNA is challenging and requires highly sensitive techniques. Classical 
methods of analysis include qRT-PCR, fluorescence and spectrophotometric approaches [76–78]. 
Digital droplet PCR has been developed as a high sensitive tool to detect ctDNA [79]. This 
technique consists in a droplet-based system [80, 81], a microfluidic platform [82, 83] and the 
so-called BEAMing strategy [84, 85]. Additionally, next-generation sequencing technology is 
currently used in plasma DNA analysis in order to identify ctDNA alterations [86–88].
6. Conclusions
There is increasing evidence that circulating tumour markers such as CTCs and ctDNA 
offer real-time information regarding cancer progression and tumour genotype in the view 
of a better systemic therapy management with direct impact on patient’s disease progno-
sis. Additionally, future characterization of these circulating markers could contribute to 
approach-specific-targeted therapies to a certain population of cancer patients.
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